China's global investment push opens doors for domestic biotechs

The U.S. market is typically the market of choice for most Chinese drugmakers when it comes to expanding business overseas.

But changes could be looming as China continues to carry on with its sweeping infrastructure project known as the Belt and Road Initiative (BRI).